|
Children's Oncology Group (CCG 09709); Villablanca, Judith G; Krailo, Mark D et al. (2006) Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 24:3423-30
|
|
Sondel, P M (1999) Post-transplant immunotherapy designed to prevent cancer recurrence. Pediatr Transplant 3 Suppl 1:96-101
|
|
Seibel, N L; Blaney, S M; O'Brien, M et al. (1999) Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. Clin Cancer Res 5:733-7
|
|
Ek, O; Reaman, G H; Crankshaw, D L et al. (1998) Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (Tomudex) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia. Leuk Lymphoma 28:509-14
|
|
Frost, J D; Hank, J A; Reaman, G H et al. (1997) A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 80:317-33
|
|
Cairo, M S (1995) The use of ifosfamide, carboplatin, and etoposide in children with solid tumors. Semin Oncol 22:23-7
|
|
Bauer, M; Reaman, G H; Hank, J A et al. (1995) A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study. Cancer 75:2959-65
|
